Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael Pohl
Observed names:
M Pohl,
M. Pohl,
Michael Pohl (9130037),
Pohl, Michael
Institutions:
University Hospitals of the Ruhr-University of Bochum,
Universitätsklinikum Knappschaftskrankenhaus Bochum,
Ruhr University Bochum
Observed institutions:
University Hospitals of the Ruhr-University of Bochum,
Universitätsklinikum Knappschaftskrankenhaus Bochum,
Knappschaftskrankenhaus Recklinghausen,
Friedrich Schiller University Jena,
Ruhr University Bochum
ORCID:
0000-0002-9706-9471
Observed ORCID:
0000-0002-9706-9471
OpenAlex ID:
A5023950338
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
2019
·
Salah-Eddin Al-Batran
, Nils Homann
, et al.
·
The Lancet
·
3,007
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
2016
·
Salah-Eddin Al-Batran
, Ralf D Hofheinz
, et al.
·
The Lancet Oncology
·
836
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial
2021
·
Emmanouil Fokas
, Anke Schlenska-Lange
, et al.
·
JAMA Oncology
·
420
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
2017
·
Salah-Eddin Al-Batran
, Thorsten O. Goetze
, et al.
·
BMC Cancer
·
257
PDF
Blood‐based detection of RAS mutations to guide anti‐ EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing
2017
·
Wolff Schmiegel
, Rodney J. Scott
, et al.
·
Molecular Oncology
·
160
PDF
Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group
2021
·
Ralf‐Dieter Hofheinz
, Susanne Hegewisch‐Becker
, et al.
·
International Journal of Cancer
·
112
PDF
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer
2019
·
Jörn Weisner
, Ina Landel
, et al.
·
Cancer Research
·
107
Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML / MDS patients
2022
·
Wanda M. Gerding
, Marco Tembrink
, et al.
·
International Journal of Cancer
·
77
PDF
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
2013
·
W. Schmiegel
, A. Reinacher-Schick
, et al.
·
Annals of Oncology
·
77
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2015
·
Sylvie Lorenzen
, Jorge Riera Knorrenschild
, et al.
·
European Journal of Cancer
·
66
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
2014
·
Ralf Hofheinz
, Susanna Hegewisch-Becker
, et al.
·
Journal of Clinical Oncology
·
63
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
2020
·
Susanne Klein-Scory
, Ingo Wahner
, et al.
·
Frontiers in Oncology
·
56
PDF
SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells.
2010
·
Michael Pohl
, Yvonne Radacz
, et al.
·
PubMed
·
50
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
2017
·
S-E. Al-Batran
, C. Pauligk
, et al.
·
Annals of Oncology
·
49
Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
2018
·
Susanne Klein-Scory
, Marina Maslova
, et al.
·
Translational Oncology
·
46
PDF
Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies
2008
·
Anke Reinacher-Schick
, Michael Pohl
, et al.
·
Nature Clinical Practice Gastroenterology & Hepatology
·
41
Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature
2011
·
M. Pohl
, N. Werner
, et al.
·
Zeitschrift für Gastroenterologie
·
32
Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow
2016
·
Michael Pohl
, Wolff Schmiegel
·
Digestive Diseases
·
29
PDF
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo
2009
·
Michael Pohl
, I. Stricker
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
28
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial
2017
·
T Götze
, N Homann
, et al.
·
Zeitschrift für Gastroenterologie
·
26
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
2023
·
Donald P. Cameron
, Jan Grosser
, et al.
·
Science Advances
·
19
Searching biomarker candidates in serum using multidimensional native chromatography. II Method evaluation with Alport syndrome and severe inflammation
2008
·
Adrienne Baum
, Michael Pohl
, et al.
·
Journal of Chromatography B
·
19
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021
·
Deepak Vangala
, Swetlana Ladigan
, et al.
·
Genome Medicine
·
17
PDF
Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response
2023
·
Susanne Klein-Scory
, Swetlana Ladigan-Badura
, et al.
·
Heliyon
·
12
Lasting response by vertical inhibition with cetuximab and trametinib inKRAS‐mutated colorectal cancer patient‐derived xenografts
2023
·
Timm M. Reissig
, Swetlana Ladigan‐Badura
, et al.
·
Molecular Oncology
·
8
PDF
Show more works
View as search
Works count:
72
Citation count:
5,649
H-index:
20
I10-index:
24
Year
Topic
Type